<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Germinal matrix and intraventricular hemorrhage (GMH-IVH) in the newborn: Management and outcome</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Germinal matrix and intraventricular hemorrhage (GMH-IVH) in the newborn: Management and outcome</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Germinal matrix and intraventricular hemorrhage (GMH-IVH) in the newborn: Management and outcome</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Linda S de Vries, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lara M Leijser, MD, PhD, MSc</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard Martin, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas R Nordli, Jr, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 15, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H17328729"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Germinal matrix and intraventricular hemorrhage (GMH-IVH; also referred to as simply IVH) is an important cause of brain injury in preterm infants. The negative impact of GMH-IVH on neurodevelopmental outcome is due not only to the direct consequences of GMH-IVH, but also to the associated complications, including posthemorrhagic ventricular dilatation (PHVD) and white matter injury (WMI).</p><p>The management, complications, outcome, and prevention of GMH-IVH in the preterm infant are discussed in this topic review. The risk factors, clinical features, and diagnosis of GMH-IVH are discussed separately. (See  <a class="medical medical_review" href="/d/html/5051.html" rel="external">"Germinal matrix and intraventricular hemorrhage (GMH-IVH) in the newborn: Risk factors, clinical features, screening, and diagnosis"</a>.)</p><p class="headingAnchor" id="H669420"><span class="h1">SEVERITY AND GRADING</span><span class="headingEndMark"> — </span>The severity of GMH-IVH is based upon the findings on cranial ultrasonography  (<a class="graphic graphic_table graphicRef69537" href="/d/graphic/69537.html" rel="external">table 1</a>) (see  <a class="medical medical_review" href="/d/html/5051.html" rel="external">"Germinal matrix and intraventricular hemorrhage (GMH-IVH) in the newborn: Risk factors, clinical features, screening, and diagnosis", section on 'Cranial ultrasound'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Grade I – Either:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bleeding that is confined to the germinal matrix (ie, GMH only)  (<a class="graphic graphic_diagnosticimage graphicRef116374" href="/d/graphic/116374.html" rel="external">image 1</a>), or </p><p class="bulletIndent2"><span class="glyph">•</span>GMH plus IVH occupying &lt;10 percent of the lateral ventricular area</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Grade II – IVH that occupies 10 to 50 percent of the lateral ventricle area  (<a class="graphic graphic_diagnosticimage graphicRef116133" href="/d/graphic/116133.html" rel="external">image 2</a>) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Grade III – IVH that occupies &gt;50 percent of the lateral ventricle area and is associated with acute ventricular dilatation  (<a class="graphic graphic_diagnosticimage graphicRef87340" href="/d/graphic/87340.html" rel="external">image 3</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Periventricular hemorrhagic infarction (PVHI; previously referred to as grade IV IVH) – Hemorrhagic infarction in periventricular white matter ipsilateral to large IVH  (<a class="graphic graphic_diagnosticimage graphicRef87222" href="/d/graphic/87222.html" rel="external">image 4</a> and <a class="graphic graphic_diagnosticimage graphicRef116149" href="/d/graphic/116149.html" rel="external">image 5</a>)</p><p></p><p>"Low-grade" or "mild" GMH-IVH refers to grades I and II and "severe" refers to grades III and PVHI (grade IV). Infants with severe GMH-IVH are at considerably higher risk of neurodevelopmental disabilities than infants with milder GMH-IVH. (See <a class="local">'Outcome'</a> below.)</p><p class="headingAnchor" id="H17328767"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Treatment of preterm infants with GMH-IVH is supportive and directed towards limiting fluctuations in cerebral perfusion, avoiding further brain injury, and early detection of complications [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H988523850"><span class="h2">Supportive care</span><span class="headingEndMark"> — </span>Supportive care for infants with GMH-IVH includes:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Blood pressure management</strong> – This includes maintaining normal blood pressure to preserve cerebral blood flow. The goal is to avoid significant or sudden perturbations and to avoid significant hypo- or hypertension. (See  <a class="medical medical_review" href="/d/html/109813.html" rel="external">"Assessment and management of low blood pressure in extremely preterm infants", section on 'Management approach'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Respiratory support</strong> – The goal is to provide adequate oxygenation and ventilation with specific avoidance of hypocarbia, hypercarbia, and acidosis. (See  <a class="medical medical_review" href="/d/html/5067.html" rel="external">"Respiratory support, oxygen delivery, and oxygen monitoring in the newborn"</a> and  <a class="medical medical_review" href="/d/html/4997.html" rel="external">"Respiratory distress syndrome (RDS) in preterm infants: Management"</a> and  <a class="medical medical_review" href="/d/html/130240.html" rel="external">"Approach to mechanical ventilation in very preterm neonates"</a> and  <a class="medical medical_review" href="/d/html/112392.html" rel="external">"Neonatal target oxygen levels for preterm infants"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fluid and nutritional support</strong> – Provision of appropriate fluid, metabolic, and nutritional support plays a key role in supporting the neonate. (See  <a class="medical medical_review" href="/d/html/5065.html" rel="external">"Fluid and electrolyte therapy in newborns"</a> and  <a class="medical medical_review" href="/d/html/5014.html" rel="external">"Approach to enteral nutrition in the premature infant"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Address thrombocytopenia and/or coagulopathy</strong> – Significant thrombocytopenia and/or coagulopathy may increase the likelihood of progressive hemorrhage in preterm neonates with established GMH-IVH. If severe GMH-IVH is present on the admission cranial ultrasound, we suggest measuring the platelet count, prothrombin time (PT), activated partial thromboplastin time (aPTT), and international normalized ratio (INR). If the aPTT and/or INR are significantly prolonged  (<a class="graphic graphic_table graphicRef65080" href="/d/graphic/65080.html" rel="external">table 2</a>), we suggest administration of fresh frozen plasma (FFP) to prevent extension of the bleed [<a href="#rid2">2</a>]. However, there is no convincing evidence to support prophylactic administration of FFP for prevention in the absence of an established GMH-IVH.</p><p></p><p class="bulletIndent1">Indications for platelet transfusion in preterm neonates are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/97752.html" rel="external">"Neonatal thrombocytopenia: Clinical manifestations, evaluation, and management", section on 'Platelet transfusion'</a>.)</p><p></p><p class="bulletIndent1">Limited data are available on the use of recombinant-activated Factor VII in neonates with IVH [<a href="#rid3">3,4</a>]. Routine use of this agent is not recommended until there are more data on its safety and efficacy in this population.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Seizure management</strong> – Seizures should be treated to avoid any associated impairment of cerebral oxygenation and cerebral perfusion, or elevations of systemic blood pressure. (See  <a class="medical medical_review" href="/d/html/6152.html" rel="external">"Clinical features, evaluation, and diagnosis of neonatal seizures"</a> and  <a class="medical medical_review" href="/d/html/6201.html" rel="external">"Treatment of neonatal seizures"</a>.)</p><p></p><p class="headingAnchor" id="H4279952818"><span class="h2">Monitoring</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serial ultrasound monitoring</strong> – For neonates with an established diagnosis of severe GMH-IVH (ie, grade III or PVHI  (<a class="graphic graphic_table graphicRef69537" href="/d/graphic/69537.html" rel="external">table 1</a>)), we suggest monitoring with twice weekly cranial ultrasound for four weeks after its onset to detect development of posthemorrhagic ventricular dilatation (PHVD; also referred to as posthemorrhagic hydrocephalus [PHH]), the major complication of severe IVH  (<a class="graphic graphic_algorithm graphicRef117895" href="/d/graphic/117895.html" rel="external">algorithm 1</a>). Details of serial ultrasound monitoring for PHVD are provided separately. (See  <a class="medical medical_review" href="/d/html/5051.html" rel="external">"Germinal matrix and intraventricular hemorrhage (GMH-IVH) in the newborn: Risk factors, clinical features, screening, and diagnosis", section on 'Serial monitoring'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical monitoring</strong> – Cranial ultrasound monitoring does not obviate the need for clinical monitoring. All affected neonates should be monitored for increasing head circumference and/or signs and symptoms of increased intracranial pressure (ICP); however, these are late findings of PHVD. Signs of elevated ICP in preterm neonates include apnea, bradycardia, irritability, sunsetting, and feeding difficulties. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Investigational monitoring techniques</strong> – Ongoing research is focused on using noninvasive neurophysiological assessments and biomarkers to identify neonates who may benefit from early intervention for PHVD. These monitoring tools include [<a href="#rid5">5-10</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Flash visual evoked potentials and amplitude integrated electroencephalography (aEEG) </p><p class="bulletIndent2"><span class="glyph">•</span>Near-infrared spectroscopy (NIRS)</p><p class="bulletIndent2"><span class="glyph">•</span>Diffuse correlation spectroscopy (DSC)</p><p class="bulletIndent2"><span class="glyph">•</span>Various possible biomarkers of IVH and PHVD (eg, activin or S100B, chemokines and cytokines, amyloid precursor protein [APP] in the cerebrospinal fluid [CSF]) </p><p></p><p class="bulletIndent1">While these tools hold promise for future clinical application, they are currently used primarily for research purposes.</p><p></p><p class="headingAnchor" id="H1886915652"><span class="h2">Management of PHVD</span><span class="headingEndMark"> — </span>PHVD is the major acute complication of severe GMH-IVH (ie, grade III or PVHI  (<a class="graphic graphic_table graphicRef69537" href="/d/graphic/69537.html" rel="external">table 1</a>)) [<a href="#rid11">11</a>]. PHVD usually begins within one to three weeks after the onset of severe IVH. The early stages of PHVD can be detected by routine ultrasound surveillance, as discussed separately. (See  <a class="medical medical_review" href="/d/html/5051.html" rel="external">"Germinal matrix and intraventricular hemorrhage (GMH-IVH) in the newborn: Risk factors, clinical features, screening, and diagnosis", section on 'Posthemorrhagic ventricular dilatation (PHVD)'</a>.)</p><p>Our approach to managing PHVD is based on early detection of asymptomatic cases identified by findings of lateral ventricular dilatation on serial ultrasound examinations  (<a class="graphic graphic_algorithm graphicRef117895" href="/d/graphic/117895.html" rel="external">algorithm 1</a>) [<a href="#rid12">12</a>]. We suggest an early treatment approach (ie, initiating treatment if cranial ultrasound demonstrates progressive ventricular dilatation) rather than waiting until clinical signs of elevated ICP are evident. </p><p class="headingAnchor" id="H2989430712"><span class="h3">Moderate-risk infants</span><span class="headingEndMark"> — </span>Moderate-risk infants are those who develop moderate ventricular dilation on serial ultrasonography (ie, ventricular index [VI] &gt;97<sup>th</sup> percentile to ≤4 mm above the 97<sup>th</sup> percentile, and anterior horn width [AHW] &gt;6 to 10 mm). (See  <a class="medical medical_review" href="/d/html/5051.html" rel="external">"Germinal matrix and intraventricular hemorrhage (GMH-IVH) in the newborn: Risk factors, clinical features, screening, and diagnosis", section on 'Serial monitoring'</a>.)</p><p>Infants with moderate-risk ventricular dilation are monitored with daily physical examination and twice weekly cranial ultrasounds  (<a class="graphic graphic_algorithm graphicRef117895" href="/d/graphic/117895.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>If the ventricular dilatation stops or stabilizes, the infant does not require treatment. Twice weekly cranial ultrasounds are continued up to four weeks and the infant should undergo neuroimaging at term-equivalent age, as discussed separately. (See  <a class="medical medical_review" href="/d/html/103308.html" rel="external">"Long-term neurodevelopmental impairment in infants born preterm: Risk assessment, follow-up care, and early intervention", section on 'Selective MRI imaging'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If there is progressive dilatation, intervention is started with initial serial lumbar punctures (LPs) followed by CSF drainage using temporary ventricular access device (VAD) and, if needed, a permanent ventriculo-peritoneal shunt (VPS). The management approach is the same as for high-risk patients. (See <a class="local">'High-risk infants'</a> below.)</p><p></p><p class="headingAnchor" id="H2273961183"><span class="h3">High-risk infants</span><span class="headingEndMark"> — </span>High-risk infants are those with significant and persistent lateral ventricular dilatation (VI &gt;4 mm above the<sup> </sup>97<sup>th</sup> percentile and anterior horn width [AHW] &gt;10 mm or thalamo-occipital distance [TOD] &gt;25 mm) [<a href="#rid12">12-16</a>]. (See  <a class="medical medical_review" href="/d/html/5051.html" rel="external">"Germinal matrix and intraventricular hemorrhage (GMH-IVH) in the newborn: Risk factors, clinical features, screening, and diagnosis", section on 'Serial monitoring'</a>.)</p><p>Our approach to management of high-risk patients is as follows  (<a class="graphic graphic_algorithm graphicRef117895" href="/d/graphic/117895.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial management (serial LPs)</strong> – Serial LPs to drain CSF are initially performed to maintain a VI &lt;4 mm above the 97<sup>th</sup> percentile for postmenstrual age (PMA). Cranial ultrasonography is performed the next day, and the decision to perform a subsequent LP is based on the findings of persistent dilatation on the follow-up study. LPs are performed no more often than once daily and restricted to 10 mL/kg per LP. (See <a class="local">'Temporary CSF drainage'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subsequent management</strong> – Subsequent management depends upon whether the dilation resolves or persists. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Resolution of PHVD</strong> – If there is no further dilatation, monitoring with cranial ultrasound is continued twice a week up to four weeks. If there is no sign of progressive dilatation during this time period and ventricular indices remain in acceptable range (VI &lt;97<sup>th</sup> percentile and AHW &lt;6 mm), the infant does not require treatment or further ultrasound monitoring. They should undergo neuroimaging at term-equivalent age, as discussed separately. (See  <a class="medical medical_review" href="/d/html/103308.html" rel="external">"Long-term neurodevelopmental impairment in infants born preterm: Risk assessment, follow-up care, and early intervention", section on 'Selective MRI imaging'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Persistent PHVD</strong> – If VI and AHW remain well above normal values and the neonate requires more than three to five serial LPs or if LPs fail to adequately decrease VI and AHW or if serial LPs are not well tolerated, we suggest placing a temporary VAD. (See <a class="local">'Temporary CSF drainage'</a> below.)</p><p></p><p class="bulletIndent2">Over the course of 7 to 10 days following VAD placement, drainage is performed once or twice a day with an initial aliquot of 10 mL/kg, with a goal of keeping the VI well below 4 mm above the 97<sup>th</sup> percentile for PMA and AHW &lt;10 mm. The frequency and volume of the drainage is modified based on daily ultrasound measurements.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for permanent shunting</strong> – Placement of a permanent CSF shunt is generally warranted for infants with persistent need for VAD drainage after four to six weeks. To be certain that the infant needs a permanent shunt, a challenge can be performed wherein VAD drainage is discontinued for 24 to 48 hours. Observing increases in VI and AHW during this period confirms the need for permanent shunt placement. (See <a class="local">'Permanent ventricular shunt'</a> below.)</p><p></p><p class="bulletIndent1">Additional criteria that are generally required prior to placement of a VPS include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The infant's weight is approximately 2 kg or higher, <strong>and</strong></p><p class="bulletIndent2"><span class="glyph">•</span>CSF protein is &lt;1.5 g/L, <strong>and</strong></p><p class="bulletIndent2"><span class="glyph">•</span>CSF red blood cell count is &lt;100/mm<sup>3</sup></p><p></p><p class="headingAnchor" id="H2584474575"><span class="h3">Symptomatic infants</span><span class="headingEndMark"> — </span>In our center, it is rare for infants with PHVD to present with clinical signs or symptoms of increased ICP (eg, bulging fontanelle, splayed cranial sutures, increasing head circumference by &gt;2 cm/week, apneas, feeding problems) because these are late findings in the course of PHVD, and we generally intervene at an earlier stage.</p><p>Nevertheless, for the rare infant with symptomatic PHVD, we suggest initiating CSF drainage by immediate insertion and tapping from a temporary VADs rather than starting with serial lumbar punctures. CSF drainage may be increased to 15 mL/kg day (divided in two separate taps), but care should be taken not to reduce the ventricular size too rapidly because this may cause hemodynamic changes and may increase the risk of rebleeding [<a href="#rid17">17</a>]. (See <a class="local">'Interventions for CSF drainage'</a> below.)</p><p class="headingAnchor" id="H1248769444"><span class="h3">Interventions for CSF drainage</span></p><p class="headingAnchor" id="H3476782818"><span class="h4">Temporary CSF drainage</span><span class="headingEndMark"> — </span>Management of progressive PHVD may include the following interventions for temporary CSF drainage [<a href="#rid1">1,18</a>]. The rationale for deferring permanent CSF shunt placement is to avoid shunt obstruction, which can occur in the acute setting immediately after a severe IVH due to high levels of protein in CSF. In addition, older infants are usually better candidates for surgery and sometimes the progression of PHVD arrests such that placement of a permanent VPS can be avoided. (See  <a class="medical medical_review" href="/d/html/5051.html" rel="external">"Germinal matrix and intraventricular hemorrhage (GMH-IVH) in the newborn: Risk factors, clinical features, screening, and diagnosis", section on 'Clinical presentation and course'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serial LPs</strong> – Serial LPs can be used as a temporizing measure in neonates with progressive PHVD to reduce the likelihood of developing clinically significant elevations in intracranial pressure. Success rates are higher if the LP is performed with the infant in a sitting position rather than lying [<a href="#rid19">19</a>]. In a 2017 meta-analysis of three clinical trials involving 233 infants with IVH, serial LPs did not appear to reduce the need for permanent CSF shunting [<a href="#rid20">20</a>]. However, in a subsequent clinical trial not included in the meta-analysis, nearly one-third of enrolled infants with PHVD were successfully managed with serial LPs alone [<a href="#rid16">16</a>]. These data are described in greater detail below. (See <a class="local">'Evidence supporting early treatment of PHVD'</a> below.) </p><p></p><p class="bulletIndent1">Additional details about performing LPs in infants, including risks associated with the procedure, are provided separately. (See  <a class="medical medical_review" href="/d/html/6325.html" rel="external">"Lumbar puncture in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>VADs</strong> – VADs are often used as a temporizing means to drain CSF to avoid or delay the need for a permanent shunt [<a href="#rid21">21-23</a>]. </p><p></p><p class="bulletIndent1">In our center, when a VAD is required, we typically use a tunneled ventricular drain with a subcutaneous reservoir, which can be tapped for CSF removal. In variations of this system, the tunneled catheter drains into an external drip chamber, surgically prepared pouch in the supraclavicular region, or the subgaleal space [<a href="#rid24">24-26</a>]. Subgaleal shunts drain continuously and do not require tapping unless drainage is inadequate or the shunt obstructs distally. Subgaleal shunts, as compared with ventricular reservoirs, reduce the need for daily CSF aspiration [<a href="#rid11">11</a>] and prolong the time period before permanent shunt placement [<a href="#rid27">27</a>]. There appears to be no difference in eventual need for permanent shunting when comparing ventricular reservoir patients and subgaleal shunt patients [<a href="#rid23">23,27,28</a>]. VAD placement can result in penetrating injury to the corpus callosum [<a href="#rid29">29</a>].</p><p></p><p class="headingAnchor" id="H2159186348"><span class="h4">Permanent ventricular shunt</span><span class="headingEndMark"> — </span>Placement of a permanent ventricular shunt for continuous CSF drainage may be required for some infants with persistent PHVD [<a href="#rid11">11,30</a>]. This most commonly consists of a ventriculoperitoneal shunt (VPS). However, VPS placement usually cannot be performed in the acute phase because the amount of blood and protein in the CSF tends to cause shunt obstruction. </p><p></p><p>VPSs can be associated with significant morbidity, especially in extremely preterm and low birth weight infants. Complications with shunts include infection and shunt malfunction. Many infants with VPSs require repeated revisions, which are thought to contribute to reduced cognitive function in this population [<a href="#rid31">31</a>]. The use of VPSs for management of hydrocephalus in infants and children is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/111138.html" rel="external">"Hydrocephalus in children: Management and prognosis", section on 'CSF shunt'</a>.)</p><p class="headingAnchor" id="H1729100413"><span class="h4">Neuroendoscopic procedures</span><span class="headingEndMark"> — </span>Neuroendoscopic procedures that are sometimes performed in infants with PHVD include endoscopic third ventriculostomy (ETV) and neuroendoscopic lavage [<a href="#rid32">32,33</a>]. The success of ETV is higher in infants &gt;6 months compared with young infants [<a href="#rid34">34</a>]. ETV is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/111138.html" rel="external">"Hydrocephalus in children: Management and prognosis", section on 'Endoscopic third ventriculostomy'</a>.)</p><p class="headingAnchor" id="H2911566239"><span class="h4">No role for diuretic therapy</span><span class="headingEndMark"> — </span>Diuretic agents such as <a class="drug drug_pediatric" data-topicid="13213" href="/d/drug information/13213.html" rel="external">acetazolamide</a> or <a class="drug drug_pediatric" data-topicid="13329" href="/d/drug information/13329.html" rel="external">furosemide</a> do <strong>not</strong> play a role in the management of PHVD. The available data suggest that these agents neither decrease the need for shunting nor reduce mortality risk and they are associated with known adverse effects (eg, nephrocalcinosis) [<a href="#rid11">11,18,35</a>].</p><p class="headingAnchor" id="H1087577898"><span class="h3">Evidence supporting early treatment of PHVD</span><span class="headingEndMark"> — </span>The practice of early intervention for high-risk PHVD (ie, prior to the onset of signs and symptoms) is supported by observational studies and limited clinical trial data [<a href="#rid16">16,36-41</a>].</p><p>The ELVIS trial (early versus late ventricular intervention study) was a multicenter clinical trial involving 126 preterm infants with PHVD who were randomly assigned to a lower or higher threshold for intervention (using the moderate- and high-risk criteria described above) [<a href="#rid16">16</a>]. The study did not detect a significant difference in the need for permanent CSF shunting in the two groups (19 percent in the early intervention group versus 23 percent in the later intervention group). A two-year follow-up study of the ELVIS trial reported on rates of severe neurodevelopmental impairment (NDI, defined as cerebral palsy [CP] or a score &gt;2 standard deviations below the mean on standardized cognitive or motor assessment [ie, Bayley Scales of Infant Development]) for 113 of the 126 infants enrolled in the trial [<a href="#rid39">39</a>]. At two years, fewer infants in the early intervention group had adverse outcome (defined as death or severe NDI) compared with the later intervention group (35 versus 51 percent; adjusted odds ratio [OR] 0.24, 95% CI, 0.07-0.87). In addition, magnetic resonance imaging at term equivalent showed less brain injury and smaller ventricular volumes for the early treatment group [<a href="#rid40">40</a>].</p><p>Similar findings were noted in an observational study that compared outcomes for infants with PHVD managed at three different institutions; two centers used an early intervention approach (similar to the approach described above) while the approach at the third center consisted of later neurosurgical intervention based upon clinical signs of elevated ICP [<a href="#rid36">36</a>]. Two-year outcomes were available for the 120 infants (73 from early intervention centers and 47 from the later intervention center). More infants managed at the early intervention centers were alive without CP at two years compared with infants managed at the later intervention center (62 versus 19 percent). In addition, more of the surviving infants in the early intervention centers had normal cognitive and motor scores at two years compared with infants managed at the later intervention center (89 versus 37 percent).  </p><p>In a meta-analysis of 66 studies (2 randomized trials [including ELVIS], 16 prospective observational studies, and 48 retrospective studies) reporting outcomes on &gt;2500 preterm infants with PHVD who underwent temporizing neurosurgical intervention, older age at time of intervention was strongly correlated with increased risk of requiring permanent shunting and increased risk of NDI [<a href="#rid41">41</a>].</p><p class="headingAnchor" id="H2535992575"><span class="h1">FOLLOW-UP</span><span class="headingEndMark"> — </span>All neonates with severe GMH-IVH require long-term neurodevelopmental follow-up. This issue is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/103308.html" rel="external">"Long-term neurodevelopmental impairment in infants born preterm: Risk assessment, follow-up care, and early intervention"</a>.)</p><p class="headingAnchor" id="H17328781"><span class="h1">OUTCOME</span></p><p class="headingAnchor" id="H619195677"><span class="h2">Acute complications</span><span class="headingEndMark"> — </span>The main complications of GMH-IVH are posthemorrhagic ventricular dilatation (PHVD) and white matter injury (WMI). These occur predominantly in infants with severe IVH (ie, grade III or PVHI). The risk of these complications is discussed separately. (See  <a class="medical medical_review" href="/d/html/5051.html" rel="external">"Germinal matrix and intraventricular hemorrhage (GMH-IVH) in the newborn: Risk factors, clinical features, screening, and diagnosis", section on 'Acute complications'</a>.)</p><p class="headingAnchor" id="H1539469874"><span class="h2">Permanent shunt placement</span><span class="headingEndMark"> — </span>Approximately 5 to 15 percent of neonates with severe IVH (ie, grade III or PVHI) ultimately require placement of a permanent ventricular shunt [<a href="#rid23">23,27,30,42</a>]. Endoscopic third ventriculostomy (ETV) is an alternative surgical procedure that is performed in a small subset of infants with PHVD. (See <a class="local">'Permanent ventricular shunt'</a> above and <a class="local">'Neuroendoscopic procedures'</a> above.)</p><p>Infants who require permanent shunt placement generally have higher risk of neurodevelopmental disabilities compared with those who do not require permanent shunting [<a href="#rid43">43</a>]. However, as discussed above, the timing of intervention also impacts the risk of neurodevelopmental disability. (See <a class="local">'Evidence supporting early treatment of PHVD'</a> above.)</p><p class="headingAnchor" id="H116727945"><span class="h2">Mortality</span><span class="headingEndMark"> — </span>The risk of mortality in infants with GMH-IVH increases with the severity of the hemorrhage. In the available studies, reported mortality rates according to GMH-IVH severity were [<a href="#rid42">42,44-46</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Grade I – 4 to 7 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Grade II – 10 to 18 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Grade III – 18 to 30 percent</p><p class="bulletIndent1"><span class="glyph">●</span>PVHI (grade IV) – 40 to 50 percent</p><p></p><p>However, it is important to recognize that infants with severe IVH often have other comorbidities that likely contribute to the high mortality risk in this population. (See  <a class="medical medical_review" href="/d/html/4966.html" rel="external">"Preterm birth: Definitions of prematurity, epidemiology, and risk factors for infant mortality", section on 'Risk factors for mortality'</a>.)</p><p class="headingAnchor" id="H116727959"><span class="h2">Long-term neurodevelopmental outcomes</span><span class="headingEndMark"> — </span>For surviving infants, the risk of long-term neurodevelopmental disabilities (eg, cerebral palsy [CP], cognitive impairment) is highest for extremely preterm infants (EPT; gestational age &lt;28 weeks) with severe IVH (ie, grade III or PVHI), especially those who develop PHVD requiring permanent shunt placement [<a href="#rid47">47-49</a>]. Infants with low-grade GMH-IVH (ie, grades I and II) have a modestly increased risk of long-term sequelae compared with those without GMH-IVH [<a href="#rid49">49-55</a>].  </p><p class="headingAnchor" id="H1132290189"><span class="h3">Low-grade GMH-IVH</span><span class="headingEndMark"> — </span>Studies are somewhat inconsistent as to whether infants with low-grade GMH-IVH (grades I and II) are at increased risk of neurodevelopmental impairment. Taken together, the available data suggest that infants with low grade GMH-IVH have a modestly higher risk of neurodevelopmental impairment (NDI) compared with infants of similar gestational age without GMH-IVH [<a href="#rid49">49-54</a>]. </p><p>In a meta-analysis of eight studies including &gt;11,000 preterm infants, the risk of severe NDI (defined as CP, severe cognitive impairment, or sensory impairment [visual impairment or hearing loss]) at age 18 to 36 months was higher in infants with low grade GMH-IVH versus those without (21 versus 17 percent; odds ratio [OR] 1.32, 95% CI 1.1-1.58) [<a href="#rid54">54</a>]. </p><p>The risks specifically for CP and severe cognitive impairment among infants with and without low-grade GMH-IVH in these studies were as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>CP – 12 versus 7.7 percent (OR 1.76, 95% CI 1.39-2.24; 10 studies, 11,018 infants); the difference was smaller in an analysis limited to studies including infants born after 2000 (10 versus 7.3 percent (OR 1.53, 95% CI 1.22-1.9; 5 studies, 5345 infants) [<a href="#rid54">54</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cognitive impairment (ie, BSID-II score &lt;70) – 25 versus 20 percent (OR 1.79, 95% CI 1.09-2.95; 4 studies 3646 infants) [<a href="#rid54">54</a>].</p><p></p><p class="headingAnchor" id="H2606293841"><span class="h3">Severe IVH</span><span class="headingEndMark"> — </span>Infants with severe IVH (grade III or PVHI) have substantially higher rates of severe NDI compared with infants without IVH born at the same gestational age [<a href="#rid30">30,42,47-50,54</a>].</p><p>In a meta-analysis of seven studies, the risk of moderate to severe NDI at age 18 to 36 months was three- to four-fold higher in infants with versus without severe IVH (unadjusted OR 3.27 [95% CI 2.44-4.39]; adjusted OR 4.26 [95% CI 3.25-5.59]) [<a href="#rid54">54</a>]. In the individual studies, reported rates of severe NDI among EPT infants with severe IVH ranged from approximately 30 to 60 percent [<a href="#rid30">30,42,48-50</a>]. This is considerably higher than the baseline risk of severe NDI in EPT infants, which is approximately 15 to 25 percent. (See  <a class="medical medical_review" href="/d/html/4967.html" rel="external">"Long-term neurodevelopmental impairment in infants born preterm: Epidemiology and risk factors", section on 'Extremely preterm infant'</a>.)</p><p>The risks specifically for CP and severe cognitive impairment were also considerably higher:</p><p class="bulletIndent1"><span class="glyph">●</span>CP – OR 4.98 (95% CI 4.13-6.0; 10 studies) [<a href="#rid54">54</a>]. In the individual studies, the risk of CP among EPT infants with grade III IVH was approximately 20 to 50 percent; the risk in infants with PVHI was 40 to 80 percent [<a href="#rid47">47-50</a>]. This is considerably higher than the baseline risk of CP in EPT infants, which is approximately 6 to 12 percent. (See  <a class="medical medical_review" href="/d/html/4967.html" rel="external">"Long-term neurodevelopmental impairment in infants born preterm: Epidemiology and risk factors", section on 'Extremely preterm infant'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cognitive impairment – OR 2.83 (95% CI 1.54-5.2; 3 studies using BSID-II) and OR 2.3 (95% CI 1.67-3.15; 2 studies using Bayley-III) [<a href="#rid54">54</a>].</p><p></p><p>For infants with severe IVH, the risk of long-term NDI is increased if there is bilateral involvement or if there is associated cystic periventricular leukomalacia (c-PVL) [<a href="#rid56">56</a>]. (See  <a class="medical medical_review" href="/d/html/5051.html" rel="external">"Germinal matrix and intraventricular hemorrhage (GMH-IVH) in the newborn: Risk factors, clinical features, screening, and diagnosis", section on 'White matter injury'</a>.)</p><p class="headingAnchor" id="H3880877077"><span class="h1">PREVENTION</span></p><p class="headingAnchor" id="H2978320841"><span class="h2">Prevention of GMH-IVH</span><span class="headingEndMark"> — </span>The most effective strategy for prevention of GMH-IVH is to reduce the incidence of preterm birth. This issue is discussed separately. (See  <a class="medical medical_review" href="/d/html/140781.html" rel="external">"Spontaneous preterm birth: Overview of interventions for risk reduction"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Obstetric care</strong> – Other obstetric practices that reduce the risk of GMH-IVH in the offspring include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Antenatal glucocorticoids for patients at risk for preterm delivery, as discussed separately (see  <a class="medical medical_review" href="/d/html/6796.html" rel="external">"Antenatal corticosteroid therapy for reduction of neonatal respiratory morbidity and mortality from preterm delivery"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Prompt recognition and appropriate treatment of intrauterine infection (clinical chorioamnionitis) (see  <a class="medical medical_review" href="/d/html/6762.html" rel="external">"Clinical chorioamnionitis", section on 'Maternal management'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neonatal care</strong> – From the neonatologist's perspective, postnatal interventions to reduce the risk of GMH-IVH generally consist of providing high-quality delivery room and postnatal care for very preterm (VPT) and extremely preterm (EPT) neonates. The goals are to provide adequate respiratory and cardiovascular support while avoiding abrupt physiologic fluctuations (eg, severe hypoxemia, hypo- or hypercapnia, hypo- or hypertension) that could contribute to reduced cerebral blood flow and increased risk of GMH-IVH. Specific postnatal risk factors for GMH-IVH are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/5051.html" rel="external">"Germinal matrix and intraventricular hemorrhage (GMH-IVH) in the newborn: Risk factors, clinical features, screening, and diagnosis", section on 'Postnatal factors'</a>.) </p><p></p><p class="bulletIndent1">Key aspects of neonatal care that may impact the risk of GMH-IVH are discussed in separate topic reviews [<a href="#rid57">57-59</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Delivery room resuscitation (see  <a class="medical medical_review" href="/d/html/5015.html" rel="external">"Neonatal resuscitation in the delivery room"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Respiratory support (see  <a class="medical medical_review" href="/d/html/5067.html" rel="external">"Respiratory support, oxygen delivery, and oxygen monitoring in the newborn"</a> and  <a class="medical medical_review" href="/d/html/4997.html" rel="external">"Respiratory distress syndrome (RDS) in preterm infants: Management"</a> and  <a class="medical medical_review" href="/d/html/130240.html" rel="external">"Approach to mechanical ventilation in very preterm neonates"</a> and  <a class="medical medical_review" href="/d/html/112392.html" rel="external">"Neonatal target oxygen levels for preterm infants"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hemodynamic support (see  <a class="medical medical_review" href="/d/html/109813.html" rel="external">"Assessment and management of low blood pressure in extremely preterm infants"</a> and  <a class="medical medical_review" href="/d/html/126605.html" rel="external">"Neonatal shock: Management"</a> and  <a class="medical medical_review" href="/d/html/16308.html" rel="external">"Management of hypertension in neonates and infants"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Restrictive red blood cell (RBC) transfusion practice (see  <a class="medical medical_review" href="/d/html/5041.html" rel="external">"Red blood cell (RBC) transfusions in the neonate", section on 'Restrictive versus liberal strategy'</a> and  <a class="medical medical_review" href="/d/html/4962.html" rel="external">"Anemia of prematurity (AOP)", section on 'Management'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Treatment of severe thrombocytopenia  (<a class="graphic graphic_algorithm graphicRef121751" href="/d/graphic/121751.html" rel="external">algorithm 2</a>) (see  <a class="medical medical_review" href="/d/html/97752.html" rel="external">"Neonatal thrombocytopenia: Clinical manifestations, evaluation, and management", section on 'Management'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Management of patent ductus arteriosus (see  <a class="medical medical_review" href="/d/html/15814.html" rel="external">"Patent ductus arteriosus (PDA) in preterm infants: Management and outcome"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In addition, we use a bundle of nursing care that includes optimal positioning (midline head position), minimal and gentle handling, avoidance of sudden leg elevation, and avoidance of rapid flushing or withdrawal of blood from intravenous lines [<a href="#rid58">58</a>]. Although it is uncertain based on the available evidence whether maintaining elevated supine midline head position reduces the risk of GMH-IVH, we continue to include this as part of routine care for preterm infants [<a href="#rid58">58-62</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interventions with uncertain or unproven efficacy </strong>– The following interventions have been studied for the prevention of GMH-IVH in preterm neonates and have been found to be ineffective or harmful, or the data are inconclusive. These interventions generally do <strong>not </strong>play a role in routine practice:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Phenobarbital (antenatal maternal or postnatal neonatal administration) [<a href="#rid63">63,64</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Maternal vitamin K [<a href="#rid65">65</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Neonatal <a class="drug drug_pediatric" data-topicid="12884" href="/d/drug information/12884.html" rel="external">vitamin E</a> supplementation [<a href="#rid66">66</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Ethamsylate (not available in the United States) [<a href="#rid67">67</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Antithrombin [<a href="#rid68">68</a>]</p><p></p><p class="headingAnchor" id="H2290317017"><span class="h2">Prevention of PHVD</span><span class="headingEndMark"> — </span>Efforts to prevent posthemorrhagic ventricular dilatation (PHVD) should focus primarily on preventing severe IVH as well as promptly recognizing severe IVH when it does occur and instituting appropriate monitoring for the neonate. (See <a class="local">'Prevention of GMH-IVH'</a> above and <a class="local">'Monitoring'</a> above.)</p><p>Other interventions aimed at preventing PHVD once severe IVH has occurred have generally not been effective. Strategies that have been studied include prophylactic CSF drainage and use of fibrinolytic agents. The rationale for these interventions is based on the assumption that PHVD is primarily due to inflammatory response of the subarachnoid villi to the presence of blood. It was hypothesized that removing inflammatory blood products from the CSF might reduce the risk of PHVD. However, these interventions have not been shown to be effective in preventing PHVD, and as a result, they are not recommended [<a href="#rid11">11</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Prophylactic CSF drainage – In a meta-analysis of three trials (233 infants) comparing prophylactic CSF drainage (with serial LPs or ventricular traps) versus no CSF drainage, the likelihood of needing a permanent shunt was similar in both groups (47 versus 45 percent; RR 0.96, 95% CI 0.73-1.26). Rates of mortality and major disability among survivors were also similar in both groups [<a href="#rid20">20</a>]. Ventricular taps should be avoided, as these will result in multiple needle tracks within the brain.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fibrinolytic agents – Studies reporting on intraventricular injection of fibrinolytic agents for prevention of PHVD have reported variable findings [<a href="#rid11">11,37,38,69,70</a>]. Based on the available data, it appears to be associated with substantial risk of adverse events, and it is unclear whether there is any benefit. As a result, fibrinolytic therapy for PHVD is not recommended for routine administration and should continue to be viewed as experimental.</p><p></p><p class="headingAnchor" id="H14142356"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to the parents or caregivers of your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/83999.html" rel="external">"Patient education: Intraventricular hemorrhage in newborns (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H17328788"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical significance</strong> ‒ Germinal matrix and intraventricular hemorrhage (GMH-IVH) is an important cause of brain injury in preterm infants. The severity of GMH-IVH is based upon the findings on cranial ultrasonography  (<a class="graphic graphic_table graphicRef69537" href="/d/graphic/69537.html" rel="external">table 1</a>). The negative impact of GMH-IVH on neurodevelopmental outcome is due not only to the direct consequences of GMH-IVH, but also to the associated complications, including posthemorrhagic ventricular dilatation (PHVD) and white matter injury (WMI). (See <a class="local">'Severity and grading'</a> above and <a class="local">'Outcome'</a> above and  <a class="medical medical_review" href="/d/html/5051.html" rel="external">"Germinal matrix and intraventricular hemorrhage (GMH-IVH) in the newborn: Risk factors, clinical features, screening, and diagnosis", section on 'Acute complications'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Treatment of GMH-IVH is supportive and directed towards preserving cerebral perfusion, avoiding further brain injury, and early detection of complications. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Supportive care</strong> – Supportive care includes blood pressure management, respiratory support, fluid and nutritional support, seizure management, and addressing clinically significant thrombocytopenia and coagulopathy. (See <a class="local">'Supportive care'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Monitoring</strong> </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Serial ultrasound monitoring</strong> – For neonates with an established diagnosis of severe GMH-IVH (ie, grade III or PVHI), we suggest monitoring with twice weekly cranial ultrasounds for four weeks after its onset to detect PHVD  (<a class="graphic graphic_algorithm graphicRef117895" href="/d/graphic/117895.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/d/html/5051.html" rel="external">"Germinal matrix and intraventricular hemorrhage (GMH-IVH) in the newborn: Risk factors, clinical features, screening, and diagnosis", section on 'Serial monitoring'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Clinical monitoring</strong> – In addition, all neonates with GMH-IVH should be monitored for increasing head circumference and/or signs and symptoms of increased intracranial pressure (ICP), which are late findings of PHVD. Signs of elevated ICP in preterm neonates include apnea, bradycardia, irritability, sunsetting, and feeding difficulties. (See <a class="local">'Monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of PHVD</strong> ‒ Our approach to managing PHVD consists of detection of asymptomatic cases using serial ultrasonography and early intervention based upon progressive ventricular dilatation rather than waiting until clinical signs of elevated ICP are evident  (<a class="graphic graphic_algorithm graphicRef117895" href="/d/graphic/117895.html" rel="external">algorithm 1</a>). (See <a class="local">'Management of PHVD'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Risk assessment</strong> – The first step is to assess the neonate's risk of progressing to severe symptomatic PHVD by trending ultrasound measurements over time. Infants with moderate ventricular dilation (ie, ventricular index [VI] &gt;97<sup>th</sup> percentile to ≤4 mm above the 97<sup>th</sup> percentile and anterior horn width [AHW] &gt;6 to ≤10 mm) are at moderate risk of developing symptomatic PHVD. Infants with more severe ventricular dilatation (ie, VI &gt;4 mm above the 97<sup>th</sup> percentile and AHW &gt;10 mm or thalamo-occipital distance [TOD] &gt;25 mm) are at high risk. (See  <a class="medical medical_review" href="/d/html/5051.html" rel="external">"Germinal matrix and intraventricular hemorrhage (GMH-IVH) in the newborn: Risk factors, clinical features, screening, and diagnosis", section on 'Serial monitoring'</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Moderate-risk infants</strong> – Infants at moderate risk are monitored with daily physical examination and twice weekly cranial ultrasounds. If the ventricular dilatation resolves or stabilizes, they do not require treatment  (<a class="graphic graphic_algorithm graphicRef117895" href="/d/graphic/117895.html" rel="external">algorithm 1</a>). (See <a class="local">'Moderate-risk infants'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>High-risk infants</strong> – For most asymptomatic high-risk infants, we suggest initiating cerebrospinal fluid (CSF) drainage rather than deferring intervention until signs and symptoms of elevated intracranial pressure develop (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Intervention consists of temporizing procedures such as serial lumbar punctures (LPs) or ventricular access device (VAD)  (<a class="graphic graphic_algorithm graphicRef117895" href="/d/graphic/117895.html" rel="external">algorithm 1</a>). (See <a class="local">'High-risk infants'</a> above and <a class="local">'Interventions for CSF drainage'</a> above and <a class="local">'Evidence supporting early treatment of PHVD'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Symptomatic infants</strong> – We also suggest initiating CSF drainage for infants with symptomatic PHVD (eg, bulging fontanelle, splayed cranial sutures, increasing head circumference by &gt;2 cm/week, apneas, feeding problems) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). VADs are typically used for CSF drainage in this setting. (See <a class="local">'Symptomatic infants'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Indications for permanent shunting</strong> – For infants who continue to require VAD drainage beyond four to six weeks, we suggest ventriculoperitoneal shunt (VPS) placement  (<a class="graphic graphic_algorithm graphicRef117895" href="/d/graphic/117895.html" rel="external">algorithm 1</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Endoscopic third ventriculostomy is an alternative procedure that is performed in a small subset of patients at some centers. VPS usually cannot be placed in the acute phase due to the neonate's small size and because the amount of blood in the CSF can cause shunt obstruction. Thus, temporary CSF drainage techniques are used until the infant is approximately 2 kg, CSF protein is &lt;1.5 g/L, and CSF red blood cell count is &lt;100/mm<sup>3</sup>. (See <a class="local">'Permanent ventricular shunt'</a> above and  <a class="medical medical_review" href="/d/html/111138.html" rel="external">"Hydrocephalus in children: Management and prognosis", section on 'CSF diversion procedures'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Follow-up</strong> – All neonates with severe GMH-IVH require long-term neurodevelopmental follow-up, as discussed separately. (See  <a class="medical medical_review" href="/d/html/103308.html" rel="external">"Long-term neurodevelopmental impairment in infants born preterm: Risk assessment, follow-up care, and early intervention"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcome </strong>‒ The risk of mortality in infants with GMH-IVH increases with the severity of the hemorrhage, ranging from approximately 5 percent in infants with grade I GMH-IVH to as high as 40 to 50 percent in infants with PVHI (grade IV IVH). Surviving infants are at increased risk of long-term neurodevelopmental disabilities (eg, cerebral palsy [CP], cognitive impairment). The risk is highest for extremely preterm infants (gestational age &lt;28 weeks) with severe IVH (ie, grade III or PVHI), especially those who develop PHVD requiring permanent shunt placement. (See <a class="local">'Outcome'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention</strong> ‒ The most effective strategy to prevent GMH-IVH is to reduce the risk of preterm birth. When preterm birth cannot be avoided, appropriate prenatal and delivery room care should be provided to the mother and neonate. This includes antenatal glucocorticoid administration, prompt resuscitative efforts, and respiratory and hemodynamic support as needed. The goals are to provide balanced respiratory and cardiovascular support while avoiding abrupt physiologic fluctuations (eg, severe hypoxemia, hypo- or hypercapnia, hypo- or hypertension). (See <a class="local">'Prevention'</a> above.)</p><p></p><p class="headingAnchor" id="H3343874866"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Lisa M Adcock, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Inder TE, Perlman JM, Volpe JJ. Preterm Intraventricular Hemorrhage/Posthemorrhagic hydrocephalus. In: Volpe's Neurology of the Newborn, 6th, Volpe JJ (Ed), Elsevier, Philadelphia 2018. p.637.</li><li><a class="nounderline abstract_t">Dani C, Poggi C, Ceciarini F, et al. Coagulopathy screening and early plasma treatment for the prevention of intraventricular hemorrhage in preterm infants. Transfusion 2009; 49:2637.</a></li><li><a class="nounderline abstract_t">Knüpfer M, Ritter J, Pulzer F, et al. IVH in VLBW Preterm Babies - Therapy with Recombinant Activated F VII? Klin Padiatr 2017; 229:335.</a></li><li><a class="nounderline abstract_t">Veldman A, Josef J, Fischer D, Volk WR. A prospective pilot study of prophylactic treatment of preterm neonates with recombinant activated factor VII during the first 72 hours of life. Pediatr Crit Care Med 2006; 7:34.</a></li><li><a class="nounderline abstract_t">Klebermass-Schrehof K, Rona Z, Waldhör T, et al. Can neurophysiological assessment improve timing of intervention in posthaemorrhagic ventricular dilatation? Arch Dis Child Fetal Neonatal Ed 2013; 98:F291.</a></li><li><a class="nounderline abstract_t">Douglas-Escobar M, Weiss MD. Biomarkers of brain injury in the premature infant. Front Neurol 2012; 3:185.</a></li><li><a class="nounderline abstract_t">Norooz F, Urlesberger B, Giordano V, et al. Decompressing posthaemorrhagic ventricular dilatation significantly improves regional cerebral oxygen saturation in preterm infants. Acta Paediatr 2015; 104:663.</a></li><li><a class="nounderline abstract_t">Morales DM, Silver SA, Morgan CD, et al. Lumbar Cerebrospinal Fluid Biomarkers of Posthemorrhagic Hydrocephalus of Prematurity: Amyloid Precursor Protein, Soluble Amyloid Precursor Protein α, and L1 Cell Adhesion Molecule. Neurosurgery 2017; 80:82.</a></li><li><a class="nounderline abstract_t">Habiyaremye G, Morales DM, Morgan CD, et al. Chemokine and cytokine levels in the lumbar cerebrospinal fluid of preterm infants with post-hemorrhagic hydrocephalus. Fluids Barriers CNS 2017; 14:35.</a></li><li><a class="nounderline abstract_t">Sunwoo J, Zavriyev AI, Kaya K, et al. Diffuse correlation spectroscopy blood flow monitoring for intraventricular hemorrhage vulnerability in extremely low gestational age newborns. Sci Rep 2022; 12:12798.</a></li><li><a class="nounderline abstract_t">Mazzola CA, Choudhri AF, Auguste KI, et al. Pediatric hydrocephalus: systematic literature review and evidence-based guidelines. Part 2: Management of posthemorrhagic hydrocephalus in premature infants. J Neurosurg Pediatr 2014; 14 Suppl 1:8.</a></li><li><a class="nounderline abstract_t">El-Dib M, Limbrick DD Jr, Inder T, et al. Management of Post-hemorrhagic Ventricular Dilatation in the Infant Born Preterm. J Pediatr 2020; 226:16.</a></li><li><a class="nounderline abstract_t">Brouwer MJ, de Vries LS, Groenendaal F, et al. New reference values for the neonatal cerebral ventricles. Radiology 2012; 262:224.</a></li><li><a class="nounderline abstract_t">Levene MI. Measurement of the growth of the lateral ventricles in preterm infants with real-time ultrasound. Arch Dis Child 1981; 56:900.</a></li><li><a class="nounderline abstract_t">Levene MI, Starte DR. A longitudinal study of post-haemorrhagic ventricular dilatation in the newborn. Arch Dis Child 1981; 56:905.</a></li><li><a class="nounderline abstract_t">de Vries LS, Groenendaal F, Liem KD, et al. Treatment thresholds for intervention in posthaemorrhagic ventricular dilation: a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed 2019; 104:F70.</a></li><li><a class="nounderline abstract_t">Cizmeci MN, de Vries LS, Tataranno ML, et al. Intraparenchymal hemorrhage after serial ventricular reservoir taps in neonates with hydrocephalus and association with neurodevelopmental outcome at 2 years of age. J Neurosurg Pediatr 2021; 28:695.</a></li><li><a class="nounderline abstract_t">Shooman D, Portess H, Sparrow O. A review of the current treatment methods for posthaemorrhagic hydrocephalus of infants. Cerebrospinal Fluid Res 2009; 6:1.</a></li><li><a class="nounderline abstract_t">Marshall ASJ, Scrivens A, Bell JL, et al. Assessment of infant position and timing of stylet removal to improve lumbar puncture success in neonates (NeoCLEAR): an open-label, 2 × 2 factorial, randomised, controlled trial. Lancet Child Adolesc Health 2023; 7:91.</a></li><li><a class="nounderline abstract_t">Whitelaw A, Lee-Kelland R. Repeated lumbar or ventricular punctures in newborns with intraventricular haemorrhage. Cochrane Database Syst Rev 2017; 4:CD000216.</a></li><li><a class="nounderline abstract_t">Berger A, Weninger M, Reinprecht A, et al. Long-term experience with subcutaneously tunneled external ventricular drainage in preterm infants. Childs Nerv Syst 2000; 16:103.</a></li><li><a class="nounderline abstract_t">Hudgins RJ, Boydston WR, Gilreath CL. Treatment of posthemorrhagic hydrocephalus in the preterm infant with a ventricular access device. Pediatr Neurosurg 1998; 29:309.</a></li><li><a class="nounderline abstract_t">Wellons JC 3rd, Shannon CN, Holubkov R, et al. Shunting outcomes in posthemorrhagic hydrocephalus: results of a Hydrocephalus Clinical Research Network prospective cohort study. J Neurosurg Pediatr 2017; 20:19.</a></li><li><a class="nounderline abstract_t">Fulmer BB, Grabb PA, Oakes WJ, Mapstone TB. Neonatal ventriculosubgaleal shunts. Neurosurgery 2000; 47:80.</a></li><li><a class="nounderline abstract_t">Zaben M, Finnigan A, Bhatti MI, Leach P. The initial neurosurgical interventions for the treatment of posthaemorrhagic hydrocephalus in preterm infants: A focused review. Br J Neurosurg 2016; 30:7.</a></li><li><a class="nounderline abstract_t">Badhiwala JH, Hong CJ, Nassiri F, et al. Treatment of posthemorrhagic ventricular dilation in preterm infants: a systematic review and meta-analysis of outcomes and complications. J Neurosurg Pediatr 2015; :1.</a></li><li><a class="nounderline abstract_t">Wang JY, Amin AG, Jallo GI, Ahn ES. Ventricular reservoir versus ventriculosubgaleal shunt for posthemorrhagic hydrocephalus in preterm infants: infection risks and ventriculoperitoneal shunt rate. J Neurosurg Pediatr 2014; 14:447.</a></li><li><a class="nounderline abstract_t">Robinson S. Neonatal posthemorrhagic hydrocephalus from prematurity: pathophysiology and current treatment concepts. J Neurosurg Pediatr 2012; 9:242.</a></li><li><a class="nounderline abstract_t">Cizmeci MN, Groenendaal F, van der Aa NE, et al. Corpus callosum injury after neurosurgical intervention for posthemorrhagic ventricular dilatation and association with neurodevelopmental outcome at 2 years. J Neurosurg Pediatr 2022; :1.</a></li><li><a class="nounderline abstract_t">Davis AS, Hintz SR, Goldstein RF, et al. Outcomes of extremely preterm infants following severe intracranial hemorrhage. J Perinatol 2014; 34:203.</a></li><li><a class="nounderline abstract_t">Arrington CN, Ware AL, Ahmed Y, et al. Are Shunt Revisions Associated with IQ in Congenital Hydrocephalus? A Meta -Analysis. Neuropsychol Rev 2016; 26:329.</a></li><li><a class="nounderline abstract_t">Schaumann A, Bührer C, Schulz M, Thomale UW. Neuroendoscopic surgery in neonates - indication and results over a 10-year practice. Childs Nerv Syst 2021; 37:3541.</a></li><li><a class="nounderline abstract_t">Parenrengi MA, Ranuh IGMAR, Suryaningtyas W. Is ventricular lavage a novel treatment of neonatal posthemorrhagic hydrocephalus? a meta analysis. Childs Nerv Syst 2023; 39:929.</a></li><li><a class="nounderline abstract_t">Zaben M, Manivannan S, Sharouf F, et al. The efficacy of endoscopic third ventriculostomy in children 1 year of age or younger: A systematic review and meta-analysis. Eur J Paediatr Neurol 2020; 26:7.</a></li><li><a class="nounderline abstract_t">Whitelaw A, Kennedy CR, Brion LP. Diuretic therapy for newborn infants with posthemorrhagic ventricular dilatation. Cochrane Database Syst Rev 2001; :CD002270.</a></li><li><a class="nounderline abstract_t">Leijser LM, Miller SP, van Wezel-Meijler G, et al. Posthemorrhagic ventricular dilatation in preterm infants: When best to intervene? Neurology 2018; 90:e698.</a></li><li><a class="nounderline abstract_t">Whitelaw A, Evans D, Carter M, et al. Randomized clinical trial of prevention of hydrocephalus after intraventricular hemorrhage in preterm infants: brain-washing versus tapping fluid. Pediatrics 2007; 119:e1071.</a></li><li><a class="nounderline abstract_t">Luyt K, Jary SL, Lea CL, et al. Drainage, irrigation and fibrinolytic therapy (DRIFT) for posthaemorrhagic ventricular dilatation: 10-year follow-up of a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed 2020; 105:466.</a></li><li><a class="nounderline abstract_t">Cizmeci MN, Groenendaal F, Liem KD, et al. Randomized Controlled Early versus Late Ventricular Intervention Study in Posthemorrhagic Ventricular Dilatation: Outcome at 2 Years. J Pediatr 2020; 226:28.</a></li><li><a class="nounderline abstract_t">Cizmeci MN, Khalili N, Claessens NHP, et al. Assessment of Brain Injury and Brain Volumes after Posthemorrhagic Ventricular Dilatation: A Nested Substudy of the Randomized Controlled ELVIS Trial. J Pediatr 2019; 208:191.</a></li><li><a class="nounderline abstract_t">Lai GY, Chu-Kwan W, Westcott AB, et al. Timing of Temporizing Neurosurgical Treatment in Relation to Shunting and Neurodevelopmental Outcomes in Posthemorrhagic Ventricular Dilatation of Prematurity: A Meta-analysis. J Pediatr 2021; 234:54.</a></li><li><a class="nounderline abstract_t">Radic JA, Vincer M, McNeely PD. Outcomes of intraventricular hemorrhage and posthemorrhagic hydrocephalus in a population-based cohort of very preterm infants born to residents of Nova Scotia from 1993 to 2010. J Neurosurg Pediatr 2015; 15:580.</a></li><li><a class="nounderline abstract_t">Adams-Chapman I, Hansen NI, Stoll BJ, et al. Neurodevelopmental outcome of extremely low birth weight infants with posthemorrhagic hydrocephalus requiring shunt insertion. Pediatrics 2008; 121:e1167.</a></li><li><a class="nounderline abstract_t">Christian EA, Jin DL, Attenello F, et al. Trends in hospitalization of preterm infants with intraventricular hemorrhage and hydrocephalus in the United States, 2000-2010. J Neurosurg Pediatr 2016; 17:260.</a></li><li><a class="nounderline abstract_t">Brouwer A, Groenendaal F, van Haastert IL, et al. Neurodevelopmental outcome of preterm infants with severe intraventricular hemorrhage and therapy for post-hemorrhagic ventricular dilatation. J Pediatr 2008; 152:648.</a></li><li><a class="nounderline abstract_t">Cizmeci MN, de Vries LS, Ly LG, et al. Periventricular Hemorrhagic Infarction in Very Preterm Infants: Characteristic Sonographic Findings and Association with Neurodevelopmental Outcome at Age 2 Years. J Pediatr 2020; 217:79.</a></li><li><a class="nounderline abstract_t">Beaino G, Khoshnood B, Kaminski M, et al. Predictors of cerebral palsy in very preterm infants: the EPIPAGE prospective population-based cohort study. Dev Med Child Neurol 2010; 52:e119.</a></li><li><a class="nounderline abstract_t">Law JB, Wood TR, Gogcu S, et al. Intracranial Hemorrhage and 2-Year Neurodevelopmental Outcomes in Infants Born Extremely Preterm. J Pediatr 2021; 238:124.</a></li><li><a class="nounderline abstract_t">Hollebrandse NL, Spittle AJ, Burnett AC, et al. School-age outcomes following intraventricular haemorrhage in infants born extremely preterm. Arch Dis Child Fetal Neonatal Ed 2021; 106:4.</a></li><li><a class="nounderline abstract_t">Bolisetty S, Dhawan A, Abdel-Latif M, et al. Intraventricular hemorrhage and neurodevelopmental outcomes in extreme preterm infants. Pediatrics 2014; 133:55.</a></li><li><a class="nounderline abstract_t">Ann Wy P, Rettiganti M, Li J, et al. Impact of intraventricular hemorrhage on cognitive and behavioral outcomes at 18 years of age in low birth weight preterm infants. J Perinatol 2015; 35:511.</a></li><li><a class="nounderline abstract_t">Payne AH, Hintz SR, Hibbs AM, et al. Neurodevelopmental outcomes of extremely low-gestational-age neonates with low-grade periventricular-intraventricular hemorrhage. JAMA Pediatr 2013; 167:451.</a></li><li><a class="nounderline abstract_t">Scott TE, Aboudi D, Kase JS. Low-Grade Intraventricular Hemorrhage and Neurodevelopmental Outcomes at 24-42 Months of Age. J Child Neurol 2020; 35:578.</a></li><li><a class="nounderline abstract_t">Rees P, Callan C, Chadda KR, et al. Preterm Brain Injury and Neurodevelopmental Outcomes: A Meta-analysis. Pediatrics 2022; 150.</a></li><li><a class="nounderline abstract_t">Uccella S, Parodi A, Calevo MG, et al. Influence of isolated low-grade intracranial haemorrhages on the neurodevelopmental outcome of infants born very low birthweight. Dev Med Child Neurol 2023.</a></li><li><a class="nounderline abstract_t">Sarkar S, Shankaran S, Barks J, et al. Outcome of Preterm Infants with Transient Cystic Periventricular Leukomalacia on Serial Cranial Imaging Up to Term Equivalent Age. J Pediatr 2018; 195:59.</a></li><li><a class="nounderline abstract_t">Chiriboga N, Cortez J, Pena-Ariet A, et al. Successful implementation of an intracranial hemorrhage (ICH) bundle in reducing severe ICH: a quality improvement project. J Perinatol 2019; 39:143.</a></li><li><a class="nounderline abstract_t">de Bijl-Marcus K, Brouwer AJ, De Vries LS, et al. Neonatal care bundles are associated with a reduction in the incidence of intraventricular haemorrhage in preterm infants: a multicentre cohort study. Arch Dis Child Fetal Neonatal Ed 2020; 105:419.</a></li><li><a class="nounderline abstract_t">Murthy P, Zein H, Thomas S, et al. Neuroprotection Care Bundle Implementation to Decrease Acute Brain Injury in Preterm Infants. Pediatr Neurol 2020; 110:42.</a></li><li><a class="nounderline abstract_t">Romantsik O, Calevo MG, Bruschettini M. Head midline position for preventing the occurrence or extension of germinal matrix-intraventricular haemorrhage in preterm infants. Cochrane Database Syst Rev 2020; 7:CD012362.</a></li><li><a class="nounderline abstract_t">Kumar P, Carroll KF, Prazad P, et al. Elevated supine midline head position for prevention of intraventricular hemorrhage in VLBW and ELBW infants: a retrospective multicenter study. J Perinatol 2021; 41:278.</a></li><li><a class="nounderline abstract_t">Kramer KP, Minot K, Butler C, et al. Reduction of Severe Intraventricular Hemorrhage in Preterm Infants: A Quality Improvement Project. Pediatrics 2022; 149.</a></li><li><a class="nounderline abstract_t">Crowther CA, Crosby DD, Henderson-Smart DJ. Phenobarbital prior to preterm birth for preventing neonatal periventricular haemorrhage. Cochrane Database Syst Rev 2010; :CD000164.</a></li><li><a class="nounderline abstract_t">Smit E, Odd D, Whitelaw A. Postnatal phenobarbital for the prevention of intraventricular haemorrhage in preterm infants. Cochrane Database Syst Rev 2013; :CD001691.</a></li><li><a class="nounderline abstract_t">Crowther CA, Crosby DD, Henderson-Smart DJ. Vitamin K prior to preterm birth for preventing neonatal periventricular haemorrhage. Cochrane Database Syst Rev 2010; :CD000229.</a></li><li><a class="nounderline abstract_t">Brion LP, Bell EF, Raghuveer TS. Vitamin E supplementation for prevention of morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2003; :CD003665.</a></li><li><a class="nounderline abstract_t">Hunt R, Hey E. Ethamsylate for the prevention of morbidity and mortality in preterm or very low birth weight infants. Cochrane Database Syst Rev 2010; :CD004343.</a></li><li><a class="nounderline abstract_t">Bruschettini M, Romantsik O, Zappettini S, et al. Antithrombin for the prevention of intraventricular hemorrhage in very preterm infants. Cochrane Database Syst Rev 2016; 3:CD011636.</a></li><li><a class="nounderline abstract_t">Luciano R, Velardi F, Romagnoli C, et al. Failure of fibrinolytic endoventricular treatment to prevent neonatal post-haemorrhagic hydrocephalus. A case-control trial. Childs Nerv Syst 1997; 13:73.</a></li><li><a class="nounderline abstract_t">Park YS, Kotani Y, Kim TK, et al. Efficacy and safety of intraventricular fibrinolytic therapy for post-intraventricular hemorrhagic hydrocephalus in extreme low birth weight infants: a preliminary clinical study. Childs Nerv Syst 2021; 37:69.</a></li></ol></div><div id="topicVersionRevision">Topic 5000 Version 57.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Inder TE, Perlman JM, Volpe JJ. Preterm Intraventricular Hemorrhage/Posthemorrhagic hydrocephalus. In: Volpe's Neurology of the Newborn, 6th, Volpe JJ (Ed), Elsevier, Philadelphia 2018. p.637.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19682341" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Coagulopathy screening and early plasma treatment for the prevention of intraventricular hemorrhage in preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29132165" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : IVH in VLBW Preterm Babies - Therapy with Recombinant Activated F VII?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16395072" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : A prospective pilot study of prophylactic treatment of preterm neonates with recombinant activated factor VII during the first 72 hours of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23258839" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Can neurophysiological assessment improve timing of intervention in posthaemorrhagic ventricular dilatation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23346073" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Biomarkers of brain injury in the premature infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25619108" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Decompressing posthaemorrhagic ventricular dilatation significantly improves regional cerebral oxygen saturation in preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27571524" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Lumbar Cerebrospinal Fluid Biomarkers of Posthemorrhagic Hydrocephalus of Prematurity: Amyloid Precursor Protein, Soluble Amyloid Precursor Proteinα, and L1 Cell Adhesion Molecule.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29228970" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Chemokine and cytokine levels in the lumbar cerebrospinal fluid of preterm infants with post-hemorrhagic hydrocephalus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35896691" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Diffuse correlation spectroscopy blood flow monitoring for intraventricular hemorrhage vulnerability in extremely low gestational age newborns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25988778" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Pediatric hydrocephalus: systematic literature review and evidence-based guidelines. Part 2: Management of posthemorrhagic hydrocephalus in premature infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32739263" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Management of Post-hemorrhagic Ventricular Dilatation in the Infant Born Preterm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22084208" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : New reference values for the neonatal cerebral ventricles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7332336" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Measurement of the growth of the lateral ventricles in preterm infants with real-time ultrasound.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7332337" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A longitudinal study of post-haemorrhagic ventricular dilatation in the newborn.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29440132" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Treatment thresholds for intervention in posthaemorrhagic ventricular dilation: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34534961" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Intraparenchymal hemorrhage after serial ventricular reservoir taps in neonates with hydrocephalus and association with neurodevelopmental outcome at 2 years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19183463" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A review of the current treatment methods for posthaemorrhagic hydrocephalus of infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36460015" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Assessment of infant position and timing of stylet removal to improve lumbar puncture success in neonates (NeoCLEAR): an open-label, 2 × 2 factorial, randomised, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28384379" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Repeated lumbar or ventricular punctures in newborns with intraventricular haemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10663817" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Long-term experience with subcutaneously tunneled external ventricular drainage in preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9973678" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Treatment of posthemorrhagic hydrocephalus in the preterm infant with a ventricular access device.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28452657" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Shunting outcomes in posthemorrhagic hydrocephalus: results of a Hydrocephalus Clinical Research Network prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10917350" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Neonatal ventriculosubgaleal shunts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26468612" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The initial neurosurgical interventions for the treatment of posthaemorrhagic hydrocephalus in preterm infants: A focused review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26314206" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Treatment of posthemorrhagic ventricular dilation in preterm infants: a systematic review and meta-analysis of outcomes and complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25148212" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Ventricular reservoir versus ventriculosubgaleal shunt for posthemorrhagic hydrocephalus in preterm infants: infection risks and ventriculoperitoneal shunt rate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22380952" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Neonatal posthemorrhagic hydrocephalus from prematurity: pathophysiology and current treatment concepts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35395637" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Corpus callosum injury after neurosurgical intervention for posthemorrhagic ventricular dilatation and association with neurodevelopmental outcome at 2 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24370654" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Outcomes of extremely preterm infants following severe intracranial hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27815765" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Are Shunt Revisions Associated with IQ in Congenital Hydrocephalus? A Meta -Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34216233" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Neuroendoscopic surgery in neonates - indication and results over a 10-year practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36622374" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Is ventricular lavage a novel treatment of neonatal posthemorrhagic hydrocephalus? a meta analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32139243" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The efficacy of endoscopic third ventriculostomy in children 1 year of age or younger: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11406041" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Diuretic therapy for newborn infants with posthemorrhagic ventricular dilatation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29367448" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Posthemorrhagic ventricular dilatation in preterm infants: When best to intervene?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17403819" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Randomized clinical trial of prevention of hydrocephalus after intraventricular hemorrhage in preterm infants: brain-washing versus tapping fluid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32623370" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Drainage, irrigation and fibrinolytic therapy (DRIFT) for posthaemorrhagic ventricular dilatation: 10-year follow-up of a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32800815" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Randomized Controlled Early versus Late Ventricular Intervention Study in Posthemorrhagic Ventricular Dilatation: Outcome at 2 Years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30878207" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Assessment of Brain Injury and Brain Volumes after Posthemorrhagic Ventricular Dilatation: A Nested Substudy of the Randomized Controlled ELVIS Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33484696" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Timing of Temporizing Neurosurgical Treatment in Relation to Shunting and Neurodevelopmental Outcomes in Posthemorrhagic Ventricular Dilatation of Prematurity: A Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26030329" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Outcomes of intraventricular hemorrhage and posthemorrhagic hydrocephalus in a population-based cohort of very preterm infants born to residents of Nova Scotia from 1993 to 2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18390958" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Neurodevelopmental outcome of extremely low birth weight infants with posthemorrhagic hydrocephalus requiring shunt insertion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26544084" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Trends in hospitalization of preterm infants with intraventricular hemorrhage and hydrocephalus in the United States, 2000-2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18410767" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Neurodevelopmental outcome of preterm infants with severe intraventricular hemorrhage and therapy for post-hemorrhagic ventricular dilatation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31706634" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Periventricular Hemorrhagic Infarction in Very Preterm Infants: Characteristic Sonographic Findings and Association with Neurodevelopmental Outcome at Age 2 Years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20163431" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Predictors of cerebral palsy in very preterm infants: the EPIPAGE prospective population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34217769" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Intracranial Hemorrhage and 2-Year Neurodevelopmental Outcomes in Infants Born Extremely Preterm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32732377" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : School-age outcomes following intraventricular haemorrhage in infants born extremely preterm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24379238" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Intraventricular hemorrhage and neurodevelopmental outcomes in extreme preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25654365" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Impact of intraventricular hemorrhage on cognitive and behavioral outcomes at 18 years of age in low birth weight preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23460139" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Neurodevelopmental outcomes of extremely low-gestational-age neonates with low-grade periventricular-intraventricular hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32438867" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Low-Grade Intraventricular Hemorrhage and Neurodevelopmental Outcomes at 24-42 Months of Age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36330752" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Preterm Brain Injury and Neurodevelopmental Outcomes: A Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36998157" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Influence of isolated low-grade intracranial haemorrhages on the neurodevelopmental outcome of infants born very low birthweight.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29398046" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Outcome of Preterm Infants with Transient Cystic Periventricular Leukomalacia on Serial Cranial Imaging Up to Term Equivalent Age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30348961" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Successful implementation of an intracranial hemorrhage (ICH) bundle in reducing severe ICH: a quality improvement project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31732682" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Neonatal care bundles are associated with a reduction in the incidence of intraventricular haemorrhage in preterm infants: a multicentre cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32473764" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Neuroprotection Care Bundle Implementation to Decrease Acute Brain Injury in Preterm Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32639053" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Head midline position for preventing the occurrence or extension of germinal matrix-intraventricular haemorrhage in preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32901115" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Elevated supine midline head position for prevention of intraventricular hemorrhage in VLBW and ELBW infants: a retrospective multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35229127" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Reduction of Severe Intraventricular Hemorrhage in Preterm Infants: A Quality Improvement Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20091502" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Phenobarbital prior to preterm birth for preventing neonatal periventricular haemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23943189" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Postnatal phenobarbital for the prevention of intraventricular haemorrhage in preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20091505" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Vitamin K prior to preterm birth for preventing neonatal periventricular haemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12917978" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Vitamin E supplementation for prevention of morbidity and mortality in preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20091562" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Ethamsylate for the prevention of morbidity and mortality in preterm or very low birth weight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26998583" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Antithrombin for the prevention of intraventricular hemorrhage in very preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9105740" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Failure of fibrinolytic endoventricular treatment to prevent neonatal post-haemorrhagic hydrocephalus. A case-control trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32661643" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Efficacy and safety of intraventricular fibrinolytic therapy for post-intraventricular hemorrhagic hydrocephalus in extreme low birth weight infants: a preliminary clinical study.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
